DOCSLIB.ORG

213026Orig1s000

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
213026Orig1s000 CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 213026Orig1s000 CLINICAL REVIEW(S) Clinical Review David Hosford, Xiang Ling, Thomas Biel, Ashutosh Rao NDA 213,026: casimersen for DMD amenable to exon 45 skipping CLINICAL REVIEW Application Type NME, original NDA Application Number(s) NDA 213,026 (IND 118,086) Priority or Standard Priority Submit Date(s) 1/10/20 (submission 1 [clinical, nonclinical]) 6/25/20 (submission 2 [quality, complete NDA]) Received Date(s) 1/10/20; 6/25/20 PDUFA Goal Date 2/25/21 Division/Office DN1 / ON / OND / CDER Reviewer Name(s) David Hosford, ; Xiang Ling (Biometrics); Thomas Biel, Ashutosh Rao (Office of Biotechnology Products [OBP]) Review Completion Date 2/15/21 Established/Proper Name Casimersen (Proposed) Trade Name Amondys 45 Applicant Sarepta Therapeutics, Inc. (Cambridge, MA) Dosage Form(s) concentrated solution in a single use-vial for IV infusion Applicant Proposed Dosing 30mg/kg weekly Regimen(s) Applicant Proposed For the treatment of Duchenne muscular dystrophy (DMD) in Indication(s)/Population(s) patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping Recommendation on Accelerated Approval Regulatory Action Recommended For the treatment of Duchenne muscular dystrophy (DMD) in Indication(s)/Population(s) patients who have a confirmed mutation of the DMD gene that (if applicable) is amenable to exon 45 skipping 1 Reference ID: 4751845 Clinical Review David Hosford, Xiang Ling, Thomas Biel, Ashutosh Rao NDA 213,026: casimersen for DMD amenable to exon 45 skipping Table of Contents Glossary ........................................................................................................................................11 1. Executive Summary...............................................................................................................14 1.1. Product Introduction......................................................................................................14 1.2. Conclusions on the Substantial Evidence of Effectiveness.............................................15 1.3. Benefit-Risk Assessment ................................................................................................16 1.4. Patient Experience Data.................................................................................................25 2. Therapeutic Context..............................................................................................................25 2.1. Analysis of Condition......................................................................................................26 2.2. Analysis of Current Treatment Options .........................................................................27 3. Regulatory Background .........................................................................................................32 3.1. U.S. Regulatory Actions and Marketing History.............................................................32 3.2. Summary of Pre-submission/Submission Regulatory Activity .......................................32 3.2.1. PIND Meeting (minutes issued 6/11/13) ................................................................33 3.2.2. Fast Track Designation Granted..............................................................................33 3.2.3. Type A Meeting (minutes issued 11/18/14) ...........................................................33 3.2.4. Partial Clinical Hold Letter (letter issued 11/9/15) .................................................34 3.2.5. Type C Meeting (minutes issued 2/15/18) .............................................................34 3.2.6. Type C Meeting (minutes issued 8/23/18) .............................................................34 3.2.7. Orphan Drug Designation .......................................................................................35 3.2.8. Pre-NDA Meeting (minutes issued 6/27/19) ..........................................................35 3.2.9. Rolling Review Granted ..........................................................................................35 3.2.10. Proprietary Name Granted..............................................................................35 3.2.11. Priority Review Granted ..................................................................................36 3.3. Foreign Regulatory Actions and Marketing History .......................................................36 4. Significant Issues from Other Review Disciplines Pertinent to Clinical Conclusions on Efficacy and Safety ................................................................................................................36 4.1. Office of Scientific Investigations (OSI) ..........................................................................36 4.2. Office of Product Quality (OPQ).....................................................................................36 4.3. Clinical Microbiology......................................................................................................37 2 Reference ID: 4751845 Clinical Review David Hosford, Xiang Ling, Thomas Biel, Ashutosh Rao NDA 213,026: casimersen for DMD amenable to exon 45 skipping 4.4. Nonclinical Pharmacology/Toxicology ...........................................................................37 4.5. Clinical Pharmacology ....................................................................................................37 4.6. Devices and Companion Diagnostic Issues ....................................................................39 4.7. Consumer Study Reviews...............................................................................................39 5. Sources of Clinical Data and Review Strategy .......................................................................39 5.1. Table of Clinical Studies .................................................................................................39 5.1.1. Description of Three Completed Studies................................................................39 5.1.2. Description of Two Ongoing Studies.......................................................................43 5.1.3. Pediatric Enrollment Data for the Five Completed or Ongoing Studies .................46 5.2. Review Strategy .............................................................................................................47 5.2.1. Efficacy Review Strategy.........................................................................................47 5.2.2. Safety Review Strategy ...........................................................................................47 6. Review of Relevant Individual Trials Used to Support Efficacy .............................................48 6.1. Study 4045-301 ..............................................................................................................48 6.1.1. Study Design..........................................................................................................48 6.1.2. Study Results ..........................................................................................................67 6.2. Efficacy Results...............................................................................................................71 6.2.1. Primary Endpoint of Interim Analysis .....................................................................71 Effects of Casimersen and Placebo on the CFB to Week 48 in Dystrophin Expression as Quantitated by Western Blot Methodology.....................................................................71 Note on Subject IDs in the Muscle Biopsy Interim Analysis that Constitutes the Efficacy Assessments .....................................................................................................................71 6.2.2. Additional Efficacy Results......................................................................................96 6.2.3. Additional Analyses Conducted on the Individual Trial ........................................110 7. Integrated Review of Effectiveness.....................................................................................122 7.1. Assessment of Efficacy Across Trials............................................................................122 7.1.1. Primary Endpoints ................................................................................................122 7.1.2. Secondary and Other Endpoints...........................................................................122 7.1.3. Subpopulations.....................................................................................................122 7.1.4. Dose and Dose-Response .....................................................................................122 7.1.5. Onset, Duration, and Durability of Efficacy Effects...............................................122 3 Reference ID: 4751845 Clinical Review David Hosford, Xiang Ling, Thomas Biel, Ashutosh Rao NDA 213,026: casimersen for DMD amenable to exon 45 skipping 7.2. Additional Efficacy Considerations...............................................................................122 7.2.1. Considerations on Benefit in the Post-market Setting .........................................122 7.2.2. Other Relevant Benefits........................................................................................124 7.3. Integrated Assessment of Effectiveness ......................................................................124 8. Review of Safety..................................................................................................................132
Load more

Recommended publications
  • Opportunities and Challenges for Antisense Oligonucleotide Therapies
    Received: 10 January 2020 Revised: 23 April 2020 Accepted: 8 May 2020 DOI: 10.1002/jimd.12251 REVIEW ARTICLE Opportunities and challenges for antisense oligonucleotide therapies Elsa C. Kuijper1 | Atze J. Bergsma2,3 | W.W.M. Pim Pijnappel2,3 | Annemieke Aartsma-Rus1 1Department of Human Genetics, Leiden University Medical Center, Leiden, The Abstract Netherlands Antisense oligonucleotide (AON) therapies involve short strands of modi- 2Department of Pediatrics, Center for fied nucleotides that target RNA in a sequence-specific manner, inducing Lysosomal and Metabolic Diseases, targeted protein knockdown or restoration. Currently, 10 AON therapies Erasmus Medical Center, Rotterdam, The Netherlands have been approved in the United States and Europe. Nucleotides are chem- 3Department of Clinical Genetics, Center ically modified to protect AONs from degradation, enhance bioavailability for Lysosomal and Metabolic Diseases, and increase RNA affinity. Whereas single stranded AONs can efficiently Erasmus Medical Center, Rotterdam, The Netherlands be delivered systemically, delivery of double stranded AONs requires capsulation in lipid nanoparticles or binding to a conjugate as the uptake Correspondence enhancing backbone is hidden in this conformation. With improved chem- Annemieke Aartsma-Rus, LUMC Postzone S4-P, Albinusdreef 2, 2333 ZA istry, delivery vehicles and conjugates, doses can be lowered, thereby reduc- Leiden, The Netherlands. ing the risk and occurrence of side effects. AONs can be used to knockdown Email: [email protected] or restore levels of protein. Knockdown can be achieved by single stranded Communicating Editor: Carla E. Hollak or double stranded AONs binding the RNA transcript and activating RNaseH-mediated and RISC-mediated degradation respectively. Transcript binding by AONs can also prevent translation, hence reducing protein levels.
    [Show full text]
  • Duchenne Muscular Dystrophy (DMD) Agents
    Therapeutic Class Overview Duchenne muscular dystrophy (DMD) Agents INTRODUCTION • Duchenne muscular dystrophy (DMD) is 1 of 4 conditions known as dystrophinopathies, which are inherited, X-linked myopathic disorders due to a defect in the dystrophin gene that results in the primary pathologic process of muscle fiber degradation. The hallmark symptom is progressive weakness (Darras 2018[a], Darras 2018[b], Muscular Dystrophy Association [MDA] 2019). The other 3 conditions include: Becker muscular dystrophy (BMD), which is a mild form of DMD; an intermediate presentation between BMD and DMD; and DMD-associated dilated cardiomyopathy, which has little or no clinical ○ skeletal or muscle disease (MDA 2019). • DMD symptom onset is in early childhood, usually between the ages of 2 and 3 years old. The proximal muscles are affected first, followed by the distal limb muscles. Generally, the lower external muscles will be affected before the upper. The affected child may have difficulties jumping, walking, and running (MDA 2019). • The prevalence of DMD ranges from 1 to 2 per 10,000 live male births; female-manifesting carriers are rarer, but can present with a range of symptoms that vary in their severities (Birnkrant et al 2018, Darras 2018[a], Emflaza Food and Drug Administration [FDA] Medical Review 2017). • The clinical course and lifespan of patients with DMD is relatively short. Individuals are usually confined to a wheelchair by age 13, and many die in their late teens or twenties from respiratory insufficiency or cardiomyopathy. Although survival until adulthood is more common now, very few patients survive past the 3rd decade (Darras 2018[a]).
    [Show full text]
  • Vyondys 53™ (Golodirsen)
    UnitedHealthcare® Commercial Medical Benefit Drug Policy Vyondys 53™ (Golodirsen) Policy Number: 2021D0088C Effective Date: April 1, 2021 Instructions for Use Table of Contents Page Related Commercial Policy Coverage Rationale ....................................................................... 1 • Provider Administered Drugs – Site of Care Applicable Codes .......................................................................... 2 Background.................................................................................... 2 Community Plan Policy Benefit Considerations .................................................................. 3 • Vyondys 53™ (Golodirsen) Clinical Evidence ........................................................................... 3 U.S. Food and Drug Administration ............................................. 3 References ..................................................................................... 4 Policy History/Revision Information ............................................. 4 Instructions for Use ....................................................................... 4 Coverage Rationale See Benefit Considerations Vyondys 53 (golodirsen) may be covered for the treatment of Duchenne muscular dystrophy (DMD) in patients who meet all of the following criteria: For initial therapy, all of the following: o Diagnosis of Duchenne muscular dystrophy by, or in consultation with, a neurologist with expertise in the diagnosis of DMD; and o Submission of medical records (e.g., chart notes, laboratory
    [Show full text]
  • The Use of Ataluren in the Effective Management of Duchenne Muscular Dystrophy
    Review Neuromuscular Diseases Early Diagnosis and Treatment – The Use of Ataluren in the Effective Management of Duchenne Muscular Dystrophy Eugenio Mercuri,1 Ros Quinlivan2 and Sylvie Tuffery-Giraud3 1. Catholic University, Rome, Italy; 2. Great Ormond Street Hospital and National Hospital for Neurology and Neurosurgery, London, UK; 3. Laboratory of Genetics of Rare Diseases (LGMR), University of Montpellier, Montpellier, France DOI: https://doi.org/10.17925/ENR.2018.13.1.31 he understanding of the natural history of Duchenne muscular dystrophy (DMD) is increasing rapidly and new treatments are emerging that have the potential to substantially improve the prognosis for patients with this disabling and life-shortening disease. For many, Thowever, there is a long delay between the appearance of symptoms and DMD diagnosis, which reduces the possibility of successful treatment. DMD results from mutations in the large dystrophin gene of which one-third are de novo mutations and two-thirds are inherited from a female carrier. Roughly 75% of mutations are large rearrangements and 25% are point mutations. Certain deletions and nonsense mutations can be treated whereas many other mutations cannot currently be treated. This emphasises the need for early genetic testing to identify the mutation, guide treatment and inform genetic counselling. Treatments for DMD include corticosteroids and more recently, ataluren has been approved in Europe, the first disease-modifying therapy for treating DMD caused by nonsense mutations. The use of ataluren in DMD is supported by positive results from phase IIb and phase III studies in which the treatment produced marked improvements in the 6-minute walk test, timed function tests such as the 10 m walk/run test and the 4-stair ascent/descent test compared with placebo.
    [Show full text]
  • Are Speci C Symptoms and Signs That Will Enable the Clinician to Recognise Disease Patterns That Will Narrow Down the Differenti
    CHILDHOOD DEVELOPMENTAL SCREENING 2020 https://doi.org/10.33591/sfp.46.5.u5 UNIT NO. 5 Brumbaugh D, Case LE, Clemens PR, Hadjiyannakis S, Pandya S, Street CHILDHOOD NEUROMUSCULAR DISORDERS examiner’s hands under the armpits and assessed for any arm periodic paralysis) and the rate of progression. An acute or delay/hypotonia, neuroimaging with MRI brain and aordable gene panels targeting neuromuscular disorders promising, with near-normal motor development in some receptor but reduced transcriptional activation and therefore 3. Orthopaedic Care neuromuscular diseases has resulted in faster and more accurate slip sign, and an attempt should be made to see if the infant can subacute onset of symptoms may be suggestive of an endocrine appropriate chromosomal/genetic testing can be considered. which are faster and less costly than whole exome or whole infants. is has resulted in new recommendations for neonatal has less side eects of other steroids. Clinical trials are still Prevention of contractures may be aected with appropriate diagnosis. Furthermore, new treatments are in the pipeline or N. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointes- A/Prof Stacey Tay Kiat Hong bear weight on both legs. e infant is then put into ventral or inammatory myositis, the chronic onset of symptoms may 2. If the child has evidence of lower limb involvement and genome sequencing. e choice of whole exome or whole newborn screening of SMA as well as a treatment algorithm for underway for head-to-head comparison of Vamorolone and resting splints of the ankles. Proper seating is also key to are already available for certain neuromuscular disorders, and 11 20 tinal and nutritional management.
    [Show full text]
  • Refreshing the Biologic Pipeline 2020
    news feature Credit: Science Lab / Alamy Stock Photo Refreshing the biologic pipeline 2020 In the absence of face-to-face meetings, FDA and industry implemented regulatory workarounds to maintain drug and biologics approvals. These could be here to stay. John Hodgson OVID-19 might have been expected since 1996) — a small miracle in itself “COVID-19 confronted us with the need to severely impair drug approvals (Fig. 1 and Table 1). to better triage sponsors’ questions,” says Cin 2020. In the event, however, To the usual crop of rare disease and Peter Marks, the director of the Center for industry and regulators delivered a small genetic-niche cancer treatments, 2020 Biologics Evaluation and Research (CBER) miracle. They found workarounds and also added a chimeric antigen receptor at the FDA. “That was perhaps the single surrogate methods of engagement. Starting (CAR)-T cell therapy with a cleaner biggest takeaway from the pandemic related in January 2020, when the outbreak veered manufacturing process and the first to product applications.” Marks says that it westward, the number of face-to face approved blockbuster indication for a became very apparent with some COVID- meetings declined rapidly; by March, small-interfering RNA (siRNA) — the 19-related files that resolving a single they were replaced by Webex and Teams. European Medicines Agency’s (EMA) issue can help a sponsor enormously and (Secure Zoom meeting are to be added registration of the RNA interference accelerate the development cycle. Before this year.) And remarkably, by 31 December, (RNAi) therapy Leqvio (inclisiran) for COVID-19, it was conceivable that a small the US Food and Drug Administration cardiovascular disease.
    [Show full text]
  • Study Protocol
    EspeRare_RIM_001 Rimeporide in DMD patients Page 1 of 85 Clinical Study Protocol Study title: A phase Ib, open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending oral doses of Rimeporide in patients with Duchenne Muscular Dystrophy Acronym: Rim4DMD Sponsor: EspeRare Foundation 14 Chemin des Aulx 1228 Plan-les-Ouates Switzerland Study Sponsor’s number: ESPERARE_RIM_001 EudraCT number: 2015-002530-50 Version: 2.1 Date: February 19th, 2016 Amendment number: 2 This document is a confidential communication of EspeRare. Acceptance of this document constitutes the agreement by the recipient that no unpublished information contained within will be published or disclosed without prior written approval, except as required to permit review by responsible Ethics Committees and Health Authorities or to obtain informed consent from potential patients. EudraCT Number 2015-002530-50 CONFIDENTIAL [Rim4DMD] – Final Version 2.1_ February 19th, 2016 EspeRare_RIM_001 Rimeporide in DMD patients Page 2 of 85 Investigator Agreement Protocol Number: EspeRare_RIM_001 EudraCT Number: 2015-002530-50 Protocol version and date: 2.1._ February 19th 2016 Sponsor: EspeRare Foundation Study drug: Rimeporide. Study title: A phase Ib, open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending oral doses of rimeporide in patients with Duchenne Muscular Dystrophy. Acronym: Rim4DMD. Investigator endorsement: I, the undersigned, am responsible for the conduct of this study at this site and agree to conduct the study according to the protocol and any approved protocol amendments, study specific procedures, all applicable laws and regulatory authority requirements including but not limited to European directives, ICH Good Clinical Practice (GCP), the Ethical principles that have their origins in the Declaration of Helsinki and applicable privacy laws.
    [Show full text]
  • Increased Dystrophin Production with Golodirsen in Patients with Duchenne Muscular Dystrophy
    Published Ahead of Print on March 5, 2020 as 10.1212/WNL.0000000000009233 ARTICLE OPEN ACCESS CLASS OF EVIDENCE Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy Diane E. Frank, PhD, Frederick J. Schnell, PhD, Cody Akana, BS, Saleh H. El-Husayni, BS, Correspondence Cody A. Desjardins, PhD, Jennifer Morgan, PhD, Jay S. Charleston, PhD, Valentina Sardone, PhD, Dr. Muntoni Joana Domingos, MD, George Dickson, PhD, Volker Straub, MD, Michela Guglieri, Eugenio Mercuri, MD, [email protected] Laurent Servais, PhD, and Francesco Muntoni, MD, on behalf of the SKIP-NMD Study Group Neurology® 2020;00:1-13. doi:10.1212/WNL.0000000000009233 Abstract MORE ONLINE Objective Class of Evidence To report safety, pharmacokinetics, exon 53 skipping, and dystrophin expression in golodirsen- Criteria for rating treated patients with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping. therapeutic and diagnostic studies Methods NPub.org/coe Part 1 was a randomized, double-blind, placebo-controlled, 12-week dose titration of once-weekly golodirsen; part 2 is an ongoing, open-label evaluation. Safety and pharmacokinetics were primary and secondary objectives of part 1. Primary biological outcome measures of part 2 were blinded exon skipping and dystrophin protein production on muscle biopsies (baseline, week 48) evaluated, respectively, using reverse transcription PCR and Western blot and immunohistochemistry. Results Twelve patients were randomized to receive golodirsen (n = 8) or placebo (n = 4) in part 1. All from part 1 plus 13 additional patients received 30 mg/kg golodirsen in part 2. Safety findings were consistent with those previously observed in pediatric patients with DMD.
    [Show full text]
  • Idebenone Protects Against Acute Murine Colitis Via Antioxidant and Anti-Inflammatory Mechanisms
    International Journal of Molecular Sciences Article Idebenone Protects against Acute Murine Colitis via Antioxidant and Anti-Inflammatory Mechanisms Sonia Shastri 1,*, Tanvi Shinde 1,2 , Sukhwinder Singh Sohal 1, Nuri Gueven 3 and Rajaraman Eri 1,* 1 Department of Laboratory Medicine, School of Health Sciences, College of Health and Medicine, University of Tasmania, Launceston, Tasmania 7250, Australia; [email protected] (T.S.); [email protected] (S.S.S.) 2 Centre for Food Safety and Innovation, Tasmanian Institute of Agriculture, University of Tasmania, Launceston, Tasmania 7250, Australia 3 Pharmacy, School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, Tasmania 7005, Australia; [email protected] * Correspondence: [email protected] (S.S.); [email protected] (R.E.); Tel.: +61-4-4992-4236 (S.S.); +61-3-6226-5017 (R.E.) Received: 3 December 2019; Accepted: 9 January 2020; Published: 12 January 2020 Abstract: Oxidative stress is a key player of the inflammatory cascade responsible for the initiation of ulcerative colitis (UC). Although the short chain quinone idebenone is considered a potent antioxidant and a mitochondrial electron donor, emerging evidence suggests that idebenone also displays anti-inflammatory activity. This study evaluated the impact of idebenone in the widely used dextran sodium sulphate (DSS)-induced mouse model of acute colitis. Acute colitis was induced in C57BL/6J mice via continuous exposure to 2.5% DSS over 7 days. Idebenone was co-administered orally at a dose of 200 mg/kg body weight. Idebenone significantly prevented body weight loss and improved the disease activity index (DAI), colon length, and histopathological score.
    [Show full text]
  • PRAC Draft Agenda of Meeting 14-17 March 2016
    14 March 2016 EMA/PRAC/199507/2016 Corr.∗ Procedure Management and Committees Support Division Pharmacovigilance Risk Assessment Committee (PRAC) Draft agenda for the meeting on 14-17 March 2016 Chair: June Raine – Vice-Chair: Almath Spooner 14 March 2016, 13:00 – 19:00, room 3/A 15 March 2016, 08:30 – 19:00, room 3/A 16 March 2016, 08:30 – 19:00, room 3/A 17 March 2016, 08:30 – 16:00, room 3/E Organisational, regulatory and methodological matters (ORGAM) 31 March 2016, 10:00 - 12:00, room 7/B, via Adobe Connect Health and safety information In accordance with the Agency’s health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting. Disclaimers Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised. Of note, this agenda is a working document primarily designed for PRAC members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted.
    [Show full text]
  • 213026Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 213026Orig1s000 OTHER REVIEW(S) IMMUNOGENICITY ASSESSMENT Application Type NDA Application Number 213026 Submit Date 01/10/2020 Received Date 01/10/2020 Division/Office CDER/OND/ON/DNI Review Completion Date 01/10/2021 Product Name Casimersen Proposed Proprie tary AMONDYS 45 Name Error! Bookmark not defined. Pharmacologic Class PMO exon Skipping Applicant Sarepta Therapeutics, Inc. (b) (4) Applicant Proposed Duchenne muscular dystrophy (DMD) in Indication(s) patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping. Immunogenicity Assessors Primary Assessor(s) Seth Thacker PhD Secondary Assessor (s) Daniela Verthelyi PhD MD Assessor Recommendation: The sponsor has submitted data for anti-dystrophin antibodies in the casimersen trials. These data were generated using assays that were developed for assessing anti-dystrophin antibodies in patients treated with eteplirsen and golodirsen and have already been deemed fit for use. The sponsor submitted anti-dystrophin ADA data for Study 4045-101, which had 12 patients enrolled No positive samples were found. The FPR for these assays in Study 4045-101 were 1.3%(IgG), 7.9% (IgE), and 39% (IgM) as calculated by the assessor. The sponsors has not submitted an assay for the detection of Casimersen-specific ADAs or provided a plan on how they assess the risk associated with the generation of novel epitopes in the dystrophin formed by exon 45 skipping. PMRs will be issued to the sponsor to develop and validate the assays and to assess the patients in study 4045-101 and 4045-301 for Abs to the product and to the peptide generated through the exon skipping strategy.
    [Show full text]
  • Annexes to the Annual Report of the European Medicines Agency 2014
    Annexes to the annual report of the European Medicines Agency 2014 Table of contents Annex 1 – Members of the Management Board ............................................................................. 2 Annex 2 – Members of the Committee for Medicinal Products for Human Use ................................... 4 Annex 3 – Members of the Pharmacovigilance Risk Assessment Committee ...................................... 6 Annex 4 – Members of the Committee for Medicinal Products for Veterinary Use ............................... 8 Annex 5 – Members of the Committee on Orphan Medicinal Products ............................................ 10 Annex 6 – Members of the Committee on Herbal Medicinal Products .............................................. 12 Annex 07 – Committee for Advanced Therapies .......................................................................... 14 Annex 8 – Members of the Paediatric Committee ........................................................................ 16 Annex 9 – Working parties and working groups .......................................................................... 18 Annex 10 – CHMP opinions in 2014 on medicinal products for human use ...................................... 22 Annex 11 – CVMP opinions in 2014 on medicinal products for veterinary use .................................. 36 Annex 12 – COMP opinions in 2014 on designation of orphan medicinal products ............................ 41 Annex 13 – HMPC European Union herbal monographs in 2014....................................................
    [Show full text]